Drug Trial Radar · NCT05836220
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
May 15, 2023
Primary completion
Aug 5, 2025
Study completion Aug 5, 2025
Sponsor
- Lead sponsor
- Pathalys PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Launch Therapeutics
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.
Conditions
- Secondary Hyperparathyroidism
- End Stage Kidney Disease
Interventions
PLS240Drug
Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
PlaceboDrug
Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
Open-Label Extension PLS240Drug
Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of PLS240 treated participants compared to the portion of placebo treated participants with a ≥30% decrease in mean iPTHTime frame: each visit from screening through week 27
- Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dLTime frame: up to week 28
- Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dLTime frame: up to week 28
- Open-Label Phase: Number of AE'sTime frame: up to week 28
- Open-Label Phase: Number of SAE'sTime frame: up to week 28
Locations
68 sites in 6 countries. Site status is shown where the registry gives one.
Site Number: USA039-2
Anaheim, California
Site Number: USA001-2
Chula Vista, California
Site Number: USA020-2
Escondido, California
Site Number: USA042-2
Fresno, California
Site Number: USA034-2
Fullerton, California
Site Number: USA046-2
Glendale, California
Site Number: USA019-2
Granada Hills, California
Site Number: USA005-2
La Mesa, California
Site Number: USA044-2
Lancaster, California
Site Number: USA030-2
Los Angeles, California
Site Number: USA043-2
Los Angeles, California
Site Number: USA022-2
Moorpark, California
Site Number: USA049-2
Northridge, California
Site Number: USA033-2
Northridge, California
Site Number: USA003-2
San Diego, California
Site Number: USA018-2
San Dimas, California
Site Number: USA056-2
Tarzana, California
Site Number: USA021-2
Tarzana, California
Site Number: USA052-2
Victorville, California
Site Number: USA023-2
Arvada, Colorado
Site Number: USA031-2
Aurora, Colorado
Site Number: USA017-2
Middlebury, Connecticut
Site Number: USA015-2
Newark, Delaware
Site Number: USA004-2
Fort Myers, Florida
Site Number: USA002-2
Hollywood, Florida
Site Number: USA041-2
Orlando, Florida
Site Number: USA035-2
South Miami, Florida
Site Number: USA013-2
Columbus, Georgia
Site Number: USA028-2
Mishawaka, Indiana
Site Number: USA024-2
Wichita, Kansas
Site Number: USA054-2
New Orleans, Louisiana
Site Number: USA048-2
Detroit, Michigan
Site Number: USA025-2
Kalamazoo, Michigan
Site Number: USA016-2
Minneapolis, Minnesota
Site Number: USA007-2
Amherst, New York
Site Number: USA053-2
Charlotte, North Carolina
Site Number: USA026-2
Durham, North Carolina
Site Number: USA009-2
Toledo, Ohio
Site Number: USA045-2
Roseburg, Oregon
Site Number: USA010-2
Greenville, South Carolina
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.